Bari Interesting: Incyte, Lilly JAK Up Phase III Program

The recent approval of Pfizer Inc.'s Janus kinase inhibitor tofacitinib, branded Xeljanz, for moderate to severe rheumatoid arthritis has investors salivating over the prospects for baricitinib, the drug in the same class for the same indication from Incyte Corp. and partner Eli Lilly and Co., entering Phase III trials.